These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19264980)

  • 1. Update in cystic fibrosis 2008.
    Ratjen F
    Am J Respir Crit Care Med; 2009 Mar; 179(6):445-8. PubMed ID: 19264980
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug developers aim to treat cystic fibrosis through disease modification.
    Thompson CA
    Am J Health Syst Pharm; 2008 Dec; 65(24):2310-2. PubMed ID: 19052266
    [No Abstract]   [Full Text] [Related]  

  • 3. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis.
    Moss RB
    J Pediatr; 2013 Apr; 162(4):676-80. PubMed ID: 23290508
    [No Abstract]   [Full Text] [Related]  

  • 4. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.
    Accurso FJ; Moss RB; Wilmott RW; Anbar RD; Schaberg AE; Durham TA; Ramsey BW;
    Am J Respir Crit Care Med; 2011 Mar; 183(5):627-34. PubMed ID: 21169471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents in cystic fibrosis.
    Storey S; Wald G
    Nat Rev Drug Discov; 2008 Jul; 7(7):555-6. PubMed ID: 18591977
    [No Abstract]   [Full Text] [Related]  

  • 6. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
    Tiddens HA; Donaldson SH; Rosenfeld M; Paré PD
    Pediatr Pulmonol; 2010 Feb; 45(2):107-17. PubMed ID: 20082341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.
    Clunes MT; Boucher RC
    Curr Opin Pharmacol; 2008 Jun; 8(3):292-9. PubMed ID: 18468487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exciting new clinical trials in cystic fibrosis: infants need not apply.
    Stick SM; Sly PD
    Am J Respir Crit Care Med; 2011 Jun; 183(12):1577-8. PubMed ID: 21693709
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease.
    Mall MA
    Exp Physiol; 2009 Feb; 94(2):171-4. PubMed ID: 19060118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epithelium as a target for therapy in cystic fibrosis.
    Thelin WR; Boucher RC
    Curr Opin Pharmacol; 2007 Jun; 7(3):290-5. PubMed ID: 17475561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amiloride: still a viable treatment option in cystic fibrosis?
    Ratjen F; Bush A
    Am J Respir Crit Care Med; 2008 Dec; 178(12):1191-2. PubMed ID: 19050201
    [No Abstract]   [Full Text] [Related]  

  • 12. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial.
    Dewitt EM; Grussemeyer CA; Friedman JY; Dinan MA; Lin L; Schulman KA; Reed SD
    Value Health; 2012; 15(2):277-83. PubMed ID: 22433759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
    Deterding RR; Lavange LM; Engels JM; Mathews DW; Coquillette SJ; Brody AS; Millard SP; Ramsey BW;
    Am J Respir Crit Care Med; 2007 Aug; 176(4):362-9. PubMed ID: 17446337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction to section I: overview of approaches to study cystic fibrosis pathophysiology.
    Clunes MT; Boucher RC
    Methods Mol Biol; 2011; 742():3-14. PubMed ID: 21547723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapies for cystic fibrosis lung disease.
    Grasemann H; Ratjen F
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):653-9. PubMed ID: 20812885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
    Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.
    Hirsh AJ; Sabater JR; Zamurs A; Smith RT; Paradiso AM; Hopkins S; Abraham WM; Boucher RC
    J Pharmacol Exp Ther; 2004 Dec; 311(3):929-38. PubMed ID: 15273255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and development of BI 1265162, an ENaC inhibitor for the treatment of cystic fibrosis.
    Betzemeier B; Braun C; Sieger P; Heckel A; Linz G; Linehan B; Veser T; Wiedenmayer D; Kley JT
    Eur J Med Chem; 2024 Feb; 265():116038. PubMed ID: 38157597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental paradigm for early features of cystic fibrosis.
    Larson JE; Cohen JC
    Pediatr Pulmonol; 2005 Nov; 40(5):371-7. PubMed ID: 15830387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New therapeutic modalities for pulmonary disease in cystic fibrosis].
    Virgilis D; Augarten A; Szeinberg A; Yahav Y
    Harefuah; 1995 Dec; 129(12):569-72. PubMed ID: 8682360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.